+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bladder Cancer Drugs Global Market Report 2022, Type, Application, Distribution Channel

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5559826
Bladder Cancer Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global bladder cancer drugs market as it emerges from the Covid 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the bladder cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Bladder Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Type: Non-Muscle-Invasive Bladder Cancer; Muscle-Invasive Bladder Cancer
2) By Application: Low-Grade Tumors; High-Grade Tumors
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Others

Companies Mentioned: Pfizer; Celgene Corporation; Eli Lilly; AstraZeneca; Bristol-Myers Squibb

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Bladder Cancer Drugs Market

What is the estimated value of the Global Bladder Cancer Drugs Market?

The Global Bladder Cancer Drugs Market was estimated to be valued at $2.35 billion in 2022.

What is the growth rate of the Global Bladder Cancer Drugs Market?

The growth rate of the Global Bladder Cancer Drugs Market is 17.3%, with an estimated value of $4.45 billion by 2026.

What is the forecasted size of the Global Bladder Cancer Drugs Market?

The Global Bladder Cancer Drugs Market is estimated to be worth $4.45 billion by 2026.

Who are the key companies in the Global Bladder Cancer Drugs Market?

Key companies in the Global Bladder Cancer Drugs Market include Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol, Myers Squibb, GlaxoSmithKline, Sanofi and La Roche.

Table of Contents

1. Executive Summary2. Bladder Cancer Drugs Market Characteristics3. Bladder Cancer Drugs Market Trends And Strategies4. Impact Of COVID-19 On Bladder Cancer Drugs
5. Bladder Cancer Drugs Market Size And Growth
5.1. Global Bladder Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Bladder Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Bladder Cancer Drugs Market Segmentation
6.1. Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Non-Muscle-Invasive Bladder Cancer
  • Muscle-Invasive Bladder Cancer
6.2. Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Low-Grade Tumors
  • High-Grade Tumors
6.3. Global Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

7. Bladder Cancer Drugs Market Regional And Country Analysis
7.1. Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Bladder Cancer Drugs Market
8.1. Asia-Pacific Bladder Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Bladder Cancer Drugs Market
9.1. China Bladder Cancer Drugs Market Overview
9.2. China Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Bladder Cancer Drugs Market
10.1. India Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Bladder Cancer Drugs Market
11.1. Japan Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Bladder Cancer Drugs Market
12.1. Australia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Bladder Cancer Drugs Market
13.1. Indonesia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Bladder Cancer Drugs Market
14.1. South Korea Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Bladder Cancer Drugs Market
15.1. Western Europe Bladder Cancer Drugs Market Overview
15.2. Western Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Bladder Cancer Drugs Market
16.1. UK Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Bladder Cancer Drugs Market
17.1. Germany Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Bladder Cancer Drugs Market
18.4. France Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Bladder Cancer Drugs Market
19.1. Eastern Europe Bladder Cancer Drugs Market Overview
19.2. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Bladder Cancer Drugs Market
20.1. Russia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Bladder Cancer Drugs Market
21.1. North America Bladder Cancer Drugs Market Overview
21.2. North America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Bladder Cancer Drugs Market
22.1. USA Bladder Cancer Drugs Market Overview
22.2. USA Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Bladder Cancer Drugs Market
23.1. South America Bladder Cancer Drugs Market Overview
23.2. South America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Bladder Cancer Drugs Market
24.1. Brazil Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Bladder Cancer Drugs Market
25.1. Middle East Bladder Cancer Drugs Market Overview
25.2. Middle East Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Bladder Cancer Drugs Market
26.1. Africa Bladder Cancer Drugs Market Overview
26.2. Africa Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Bladder Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Bladder Cancer Drugs Market Competitive Landscape
27.2. Bladder Cancer Drugs Market Company Profiles
27.2.1. Pfizer
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Celgene Corporation
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Eli Lilly
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. AstraZeneca
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Bristol-Myers Squibb
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Bladder Cancer Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Bladder Cancer Drugs Market30. Bladder Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson.

The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.

The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is cancer that develops in the tissue that lines the bladder’s inner surface. There is no involvement of the bladder muscle. The different applications include low-grade tumors, high-grade tumors and distributed through various channels such as hospital pharmacy, retail pharmacy, others.

North America is the largest region in the bladder cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the Center for Drug Research And Development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology.

The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Sanofi
  • Hoffmann-La Roche
  • Novartis International
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Vault Pharma Inc.
  • Vyriad Inc.
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Asieris Pharmaceuticals Co. Ltd.
  • Asana BioSciences LLC
  • Array BioPharma Inc.
  • Archivel Farma SL
  • AndroScience Corp.
  • Amgen Inc.
  • Altor BioScience Corp.
  • Alligator Bioscience AB
  • Adaptimmune Therapeutics Plc.

Methodology

Loading
LOADING...